Compendium of Cancer Genome Aberrations

Changes

Translocations et al. in Hematological Cancers (view source)

Revision as of 14:21, 31 July 2016

123 bytes removed ,  14:21, 31 July 2016
→‎Translocations Long List
Line 30: Line 30:  
|-
 
|-
 
|[[t(1;5)(q22;q33)]]
 
|[[t(1;5)(q22;q33)]]
−
|[[MPD with eosinophilia]],[[ CEL]],[[ B-ALL]]
+
|[[MPD]],[[ CEL]],[[ B-ALL]]
 
|[[PDE4DIP-PDGFRB]]
 
|[[PDE4DIP-PDGFRB]]
 
|-
 
|-
Line 42: Line 42:  
|-
 
|-
 
|[[t(1;14)(q21;q32)]]
 
|[[t(1;14)(q21;q32)]]
−
|[[B-ALL]],[[ NHL]]
+
|[[B-ALL]],[[NHL]]
 
|[[IGH-BCL9]],[[IGH-FCGR2B]],[[IGH-FCRL4]],[[IGH-MUC1]]
 
|[[IGH-BCL9]],[[IGH-FCGR2B]],[[IGH-FCRL4]],[[IGH-MUC1]]
 
|-
 
|-
Line 58: Line 58:  
|-
 
|-
 
|[[t(2;5)(p23;q35)]]
 
|[[t(2;5)(p23;q35)]]
−
|[[ALCL]],[[ NHL]]
+
|[[ALCL]],[[NHL]]
 
|[[NPM1-ALK]]
 
|[[NPM1-ALK]]
 
|-
 
|-
 
|[[t(2;8)(p12;q24.1)]]
 
|[[t(2;8)(p12;q24.1)]]
−
|[[BL]],[[ B-ALL]],[[ NHL ]]
+
|[[BL]],[[ B-ALL]],[[NHL]]
 
|[[MYC]]
 
|[[MYC]]
 
|-
 
|-
Line 73: Line 73:  
|
 
|
 
|-
 
|-
−
|[[Translocation t(3;3)(q21;q26.2) and Inversion inv(3)(q21q26.2)|t(3;3)(q21;q26.2) ]]
+
|[[Translocation t(3;3)(q21;q26.2) and Inversion inv(3)(q21q26.2)|t(3;3)(q21;q26.2)]]
 
|[[MDS]],[[AML]]
 
|[[MDS]],[[AML]]
 
|[[RPN1-MECOM(EVI1)]]
 
|[[RPN1-MECOM(EVI1)]]
Line 98: Line 98:  
|-
 
|-
 
|[[t(4;5;5)(q23;q31;q33)]]
 
|[[t(4;5;5)(q23;q31;q33)]]
−
|[[chronic basophilic leukemia]]
+
|[[Chronic Basophilic Leukemia]]
 
|[[PRKG2-PDGFRB]]
 
|[[PRKG2-PDGFRB]]
 
|-
 
|-
Line 114: Line 114:  
|-
 
|-
 
|[[t(5;12)(q33;q24)]]
 
|[[t(5;12)(q33;q24)]]
−
|[[MPD with eosinophilia  ]]
+
|[[MPD]]
 
|[[GIT2-PDGFRB]]
 
|[[GIT2-PDGFRB]]
 
|-
 
|-
 
|[[t(5;12)(q33;p13)]]
 
|[[t(5;12)(q33;p13)]]
−
|[[CMML]],[[ MDS]],[[ MPD]]
+
|[[CMML]],[[MDS]],[[MPD]]
 
|[[ETV6(TEL)-PDGFRB]]
 
|[[ETV6(TEL)-PDGFRB]]
 
|-
 
|-
 
|[[t(5;14)(q33;q24)]]
 
|[[t(5;14)(q33;q24)]]
−
|[[MPD]],[[ atypical MPD]]
+
|[[MPD]],[[MPD]]
 
|[[NIN-PDGFRB]]
 
|[[NIN-PDGFRB]]
 
|-
 
|-
Line 130: Line 130:  
|-
 
|-
 
|[[t(5;15)(q33;q22)]]
 
|[[t(5;15)(q33;q22)]]
−
|[[CMML atypical MPD]]
+
|[[CMML]],[[MPD]]
 
|[[TP53BP1-PDGFRB]]
 
|[[TP53BP1-PDGFRB]]
 
|-
 
|-
Line 142: Line 142:  
|-
 
|-
 
|[[der(5;17)(p10;q10)]]
 
|[[der(5;17)(p10;q10)]]
−
|[[MDS]],[[ AML]]
+
|[[MDS]],[[AML]]
 
|[[NPM1(NPM)-RARA]]
 
|[[NPM1(NPM)-RARA]]
 
|-
 
|-
Line 150: Line 150:  
|-
 
|-
 
|[[t(5;17)(q33;p13)]]
 
|[[t(5;17)(q33;p13)]]
−
|[[CMML]],[[ atypical MPD]]
+
|[[CMML]],[[MPD]]
 
|[[RABEP1-PDGFRB ]]
 
|[[RABEP1-PDGFRB ]]
 
|-
 
|-
Line 162: Line 162:  
|-
 
|-
 
|[[t(6;11)(q27;q23) ]]
 
|[[t(6;11)(q27;q23) ]]
−
|[[AML]],[[ t-AML]],[[ T-ALL]]
+
|[[AML]],[[ t-AML]],[[T-ALL]]
 
|[[KMT2A-MLLT4]]
 
|[[KMT2A-MLLT4]]
 
|-
 
|-
Line 173: Line 173:  
|[[IGH-MYC]]
 
|[[IGH-MYC]]
 
|-
 
|-
−
|[[t(8;16)(p11.2;p13.3) A]]
+
|[[t(8;16)(p11.2;p13.3)]]
 
|[[AML]],[[t-MDS]]
 
|[[AML]],[[t-MDS]]
 
|[[KAT6A(MYST3)-CREBBP(CBP)]]
 
|[[KAT6A(MYST3)-CREBBP(CBP)]]
 
|-
 
|-
 
|[[t(8;21)(q22;q22) A ]]
 
|[[t(8;21)(q22;q22) A ]]
−
|[[AML M2 mostly]],[[ rarely M1]],[[ M4]]
+
|[[AML]]
 
|[[RUNX1(AML)-RUNX1T1(ETO)]]
 
|[[RUNX1(AML)-RUNX1T1(ETO)]]
 
|-
 
|-
 
|[[t(8;22)(q24.1;q11.2) ]]
 
|[[t(8;22)(q24.1;q11.2) ]]
−
|[[BL]],[[ B-ALL]],[[ NHL]],[[ MM]]
+
|[[BL]],[[ B-ALL]],[[NHL]],[[ MM]]
 
|[[IGL-MYC]]
 
|[[IGL-MYC]]
 
|-
 
|-
Line 194: Line 194:  
|-
 
|-
 
|[[t(9;14)(p13;q32)]]
 
|[[t(9;14)(p13;q32)]]
−
|[[MM]],[[CLL]],[[DLBCL]],[[ FL]],[[MCL splenic MZL]]
+
|[[MM]],[[CLL]],[[DLBCL]],[[FL]],[[MCL splenic MZL]]
 
|[[PAX5-IGH]]
 
|[[PAX5-IGH]]
 
|-
 
|-
 
|[[t(9;22)(q34;q11.2)]]
 
|[[t(9;22)(q34;q11.2)]]
−
|[[CML]],[[ B-ALL]],[[ T-ALL]]
+
|[[CML]],[[ B-ALL]],[[T-ALL]]
 
|[[ABL1(ABL)-BCR]]
 
|[[ABL1(ABL)-BCR]]
 
|-
 
|-
 
|[[t(11;14)(q13;q32)]]
 
|[[t(11;14)(q13;q32)]]
 
|[[MCL]],[[ MM]]
 
|[[MCL]],[[ MM]]
−
|[[CCND1(BCL1)- IGH]]
+
|[[IGH-CCND1]]
 
|-
 
|-
 
|[[t(11;14)(q23;q32)]]
 
|[[t(11;14)(q23;q32)]]
−
|[[t-AML]]
+
|[[AML]]
 
|[[KMT2A-KIAA0284]]
 
|[[KMT2A-KIAA0284]]
 
|-
 
|-
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/1573"